GRACE Score: ACS Risk Stratification & Heart Attack Management | RxMedCalc
How to calculate GRACE in-hospital and 6-month mortality risk, what each risk category means for management, invasive vs conservative strategy timing, antiplatelet therapy, and ACS in India.
A patient arrives in your emergency department with chest pain. The ECG shows no ST elevation. Troponin is being sent. Is this person at low risk — muscle pain or oesophageal spasm — or are they in the middle of a heart attack that will kill them tonight? And if it is a heart attack, do they need the cath lab in the next 2 hours, 24 hours, or can they be stabilised medically?
The GRACE score (Global Registry of Acute Coronary Events) is the tool that answers these questions. Derived from over 100,000 patients across 14 countries, it uses eight clinical variables to precisely predict in-hospital and 6-month mortality in patients with acute coronary syndrome (ACS) — and directly drives the most consequential treatment decision in cardiology: when to take the patient to the catheterisation laboratory.
Understanding Acute Coronary Syndrome
Acute coronary syndrome is an umbrella term for three related conditions caused by reduced blood flow to the heart, usually from coronary artery plaque rupture and thrombus formation:
- STEMI (ST-Elevation Myocardial Infarction): Complete coronary artery occlusion. ST elevation on ECG. Requires immediate reperfusion — primary PCI within 90 minutes (door-to-balloon) or thrombolysis within 30 minutes if PCI unavailable. GRACE score is less relevant here — all STEMI patients need immediate intervention.
- NSTEMI (Non-ST-Elevation MI): Partial occlusion. Troponin elevated without ST elevation. This is where GRACE score drives management — timing of angiography is risk-stratified.
- Unstable Angina (UA): Chest pain at rest or minimal exertion. Troponin normal. The boundary between UA and NSTEMI has blurred with high-sensitivity troponin assays.
Together, NSTEMI and UA are referred to as NSTE-ACS — the primary domain of the GRACE score.
The GRACE Score Variables
| Variable | What It Captures | Clinical Note |
|---|---|---|
| Age | Each decade significantly increases mortality | Strongest single predictor — age > 75 carries very high risk |
| Heart Rate | Tachycardia reflects haemodynamic compromise | HR > 100 bpm at presentation adds significant points |
| Systolic BP | Hypotension = cardiogenic shock risk | SBP < 100 mmHg adds very high points; low BP = high risk |
| Creatinine | Renal impairment worsens ACS outcomes dramatically | Even mild elevation (1.2–1.5 mg/dL) adds significant risk |
| Killip Class | Degree of heart failure at presentation | Class I = no CHF; Class II = rales; Class III = pulmonary oedema; Class IV = cardiogenic shock |
| Cardiac Arrest at Admission | Resuscitated cardiac arrest = very high risk | Binary yes/no — adds large number of points if yes |
| ST-Segment Deviation | ECG changes reflecting ischaemia severity | ST depression or transient elevation in NSTE-ACS adds points |
| Elevated Cardiac Biomarkers | Positive troponin = myocardial necrosis confirmed | Positive troponin significantly increases GRACE score |
GRACE Score Risk Categories — In-Hospital Mortality
6-month mortality < 3%
6-month mortality 3–8%
6-month mortality > 8%
❤️ Use the RxMedCalc GRACE Score Calculator — calculates in-hospital and 6-month mortality with automatic risk stratification and ESC 2023 invasive strategy timing guidance.
From GRACE Score to Management — Invasive Strategy Timing
The single most important application of the GRACE score in NSTE-ACS is determining when to perform coronary angiography (with a view to PCI or CABG):
| Condition / Risk | Strategy | Timing |
|---|---|---|
| Very high risk — any of: haemodynamic instability, cardiogenic shock, refractory chest pain, acute heart failure, life-threatening arrhythmias, mechanical complications | Immediate invasive | Within 2 hours — regardless of GRACE score |
| High risk — GRACE > 140, dynamic ECG changes, elevated troponin, or GRACE < 140 but HEART score high | Early invasive | Within 24 hours |
| Intermediate risk — GRACE 109–140, diabetes, renal impairment, reduced EF < 40%, prior PCI/CABG, recurrent symptoms | Invasive within 72 hours | 24–72 hours |
| Low risk — GRACE ≤ 108, no high-risk features, non-obstructive CAD or normal angiogram possible | Conservative / selective invasive | Non-invasive testing first (stress echo, CT coronary angiography) before angiography decision |
⚠️ Very high risk features override GRACE score. A patient with cardiogenic shock or refractory ischaemia goes to the cath lab immediately — regardless of what the GRACE score calculates. GRACE guides timing; it does not replace clinical urgency assessment.
Killip Classification — The Heart Failure Component
The Killip class is one of the variables in the GRACE score and also stands alone as an important bedside assessment of cardiac failure severity in ACS:
| Killip Class | Clinical Features | In-Hospital Mortality (Historical) |
|---|---|---|
| Class I | No evidence of heart failure — no rales, no S3 | ~6% |
| Class II | Mild-moderate heart failure — basal rales < 50% of lung fields, S3 gallop, elevated JVP | ~17% |
| Class III | Severe heart failure — pulmonary oedema, rales > 50% of lung fields | ~38% |
| Class IV | Cardiogenic shock — hypotension + end-organ hypoperfusion (cold extremities, oliguria, altered consciousness) | > 60% |
Antithrombotic Therapy in NSTE-ACS
Dual Antiplatelet Therapy (DAPT)
All NSTE-ACS patients without contraindication should receive aspirin + a P2Y12 inhibitor as soon as the diagnosis is established:
- Aspirin: 300 mg loading dose (chewed for fastest absorption), then 75–100 mg daily indefinitely
- Ticagrelor (preferred): 180 mg loading, then 90 mg twice daily × 12 months. Faster onset, more reliable platelet inhibition than clopidogrel.
- Clopidogrel: 300–600 mg loading, then 75 mg daily × 12 months. Used when ticagrelor is unavailable, too expensive, or contraindicated. Widely used in India due to cost.
- Prasugrel: 60 mg loading, then 10 mg daily. More potent than clopidogrel. Avoid in patients > 75 years, weight < 60 kg, or history of TIA/stroke.
Anticoagulation
All NSTE-ACS patients should also receive anticoagulation in addition to antiplatelet therapy:
- Fondaparinux 2.5 mg SC daily — preferred for most NSTE-ACS patients not going immediately to angiography (lower bleeding risk than LMWH in OASIS-5 trial)
- Enoxaparin (LMWH) 1 mg/kg SC BD — alternative, widely used in India; dose-adjust for eGFR < 30 mL/min
- Unfractionated heparin (UFH) — preferred when immediate PCI is planned (reversible with protamine, can be given intra-arterially)
High-Sensitivity Troponin — Changing ACS Diagnosis
The introduction of high-sensitivity troponin (hs-Tn) assays has transformed NSTE-ACS diagnosis. The ESC 0/1-hour or 0/2-hour algorithm using hs-Tn allows rapid rule-in or rule-out of NSTEMI:
- 0h hs-Tn very low AND low clinical probability → rule out NSTEMI within 1 hour
- 0h hs-Tn high OR significant rise at 1/2 hours → rule in NSTEMI → GRACE score for management
- Intermediate zone → 3-hour or serial testing + GRACE score
In India, hs-Tn assays are increasingly available in tertiary and secondary care centres. Where conventional troponin is still used, 6-hourly serial testing remains the standard.
ACS in India — Key Differences
ACS in India has several important epidemiological and clinical features that differ from Western populations:
- Younger age at presentation: Mean age of first MI in Indian men is approximately 53 years — nearly a decade earlier than in Western cohorts. A significant proportion of ACS patients are under 40.
- Higher risk despite lower BMI: Indians develop CAD at lower body weight due to visceral adiposity, insulin resistance, and high Lp(a) levels.
- Predominantly STEMI: STEMI is more common than NSTEMI in India — partly because many patients present late (after the troponin has peaked and ECG ST elevation has evolved), and partly due to differences in coronary plaque morphology.
- Thrombolysis remains common: Primary PCI is the gold standard but is only available at major cardiac centres. In India, a large proportion of STEMI patients still receive thrombolysis (streptokinase or tenecteplase) due to cath lab unavailability or delayed presentation.
- Diabetes prevalence: India has one of the world's highest T2DM burdens — diabetic patients have worse ACS outcomes, more multivessel disease, and less typical symptoms (more silent MI).
Key Takeaways
- GRACE uses 8 variables: age, HR, SBP, creatinine, Killip class, cardiac arrest, ST deviation, troponin
- GRACE ≤ 108 = low risk; 109–140 = intermediate; > 140 = high risk
- High risk → angiography within 24 hours; very high risk features → within 2 hours
- All NSTE-ACS: aspirin + ticagrelor (or clopidogrel) + anticoagulation immediately
- Killip Class IV (cardiogenic shock) = immediate catheterisation regardless of score
- hs-Tn 0/1-hour algorithm enables rapid rule-in or rule-out of NSTEMI
- Indian ACS: younger, leaner, more diabetic, more STEMI than Western populations — GRACE still validated
- GRACE is for NSTE-ACS — STEMI always requires immediate reperfusion
References
- Fox KA et al. Prediction of risk of death and myocardial infarction in the six months after presentation with acute coronary syndrome: prospective multinational observational study (GRACE). BMJ. 2006;333(7578):1091.
- Collet JP et al. 2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur Heart J. 2021;42(14):1289-1367.
- Reyes AT et al. ESC 2023 Update on ACS guidelines. Eur Heart J. 2023.
- Pais P et al. Risk factors for acute myocardial infarction in Indians — a case-control study. Lancet. 1996;348(9024):358-363.
- Cardiology Society of India. CSI Consensus Guidelines on Management of ACS in India. Indian Heart J. 2020.
This article is for educational purposes based on ESC 2023 and CSI guidelines. ACS management decisions — including timing of angiography and antiplatelet/anticoagulant choice — must be made by a qualified cardiologist with full clinical assessment.
Built by an MBBS, AFIH Certified Physician in Punjab, India | RxMedCalc.com